New hope for stomach cancer: triple therapy targets tough tumors
NCT ID NCT06206733
First seen Jan 28, 2026 · Last updated May 22, 2026 · Updated 17 times
Summary
This study tests a new drug called ASKB589 added to standard chemotherapy and immunotherapy for people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2). The goal is to see if the combination helps keep the cancer from growing longer than standard treatment alone. About 780 participants will receive either the new drug or a placebo, along with chemo and immunotherapy, as their first treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing cancer hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.